Document:

EX-10.21

 Exhibit 10.21 

ROYALTY TRANSFER AGREEMENT 

This Royalty Transfer Agreement (the “Agreement”) is made and entered into on [date] (the “Effective Date”), by and
between [Cullinan Asset Subsidiary], a Delaware corporation (the “Company”), MPM Oncology Charitable Foundation, Inc., a Massachusetts charitable foundation (the “MPM Charitable Foundation”) and the UBS Optimus
Foundation, a Swiss charitable foundation (“Optimus,” and together with the MPM Charitable Foundation, each a “Charitable Foundation” and together the “Charitable Foundations”).

WHEREAS, certain investors of the Company have requested that the Company enter into this Agreement providing for the transfer of 1.0%
of Net Sales on the terms and conditions outlined below; and 
 WHEREAS, the Company is willing to enter into this Agreement in
connection with such request. 
 NOW, THEREFORE, the Company, the MPM Charitable Foundation and Optimus agree as follows: 

Section 1: Definitions 
 Definitions. The
following terms, as used herein, have the following meanings: 
 “Affiliate” shall mean any legal entity (such as a corporation,
partnership, limited liability company, etc.) that is directly or indirectly controlled by, or is under common control with, the Company. For the purposes of this definition, “control” shall mean direct or indirect (i) beneficial
ownership of at least 50% of the voting securities of a legal entity, or (ii) a 50% or greater interest in the net assets or profits of a legal entity. 

“Bad Debt” shall mean any amounts booked as such on the Company’s financial statements, prepared in accordance with GAAP. 

“Company IP” shall mean (a) any invention and/or (b) any patents and/or patent applications in each case which is in whole or in
part developed by, or otherwise becomes owned or controlled by, the Company. 
 “Company Products” shall mean any product developed or
owned by the Company requiring pre-market regulatory approval, provided that any product developed or owned by the Company that references, practices or
incorporates, or (if such intellectual property was not owned or controlled by the Company), would infringe, only Post-IPO IP shall not be deemed a “Company Product” hereunder. Further,
notwithstanding anything to the contrary herein, for the avoidance of doubt, Company Products shall not include any products that are discovered, developed, manufactured and/or commercialized by or on behalf of, or are covered by intellectual
property (whether or not patentable) of, any person or entity that is an acquiror or merger partner of Company, becomes an Affiliate or successor of the Company by reason of any transaction in connection with the sale of all or substantially all of
the stock and/or assets of the Company related to such product (such transaction, an “Acquisition”), or an assignee of this Agreement in 

 
connection with any of the aforementioned transactions, provided that the discovery, development, manufacture and/or commercialization of such product are performed without use of Pre-Acquisition IP. 
 “End of the Year” shall mean December 31 of a given calendar year. 

“Licensee” shall mean any party that is not an Affiliate that has been granted a license to the applicable Company Product(s). 

“Net Sales” means, with respect to a Company Product, the gross amounts invoiced in arm’s length transactions by the Company or its
Affiliates or Licensees to third parties for sales of such Company Product, less good faith estimates of the following deductions to the extent specifically relating to sales of such Company Product, which will be adjusted to reflect actual
deductions on a periodic basis (no less frequently than annually): 
  

	 	a)	 discounts (including trade, quantity, and cash discounts) actually allowed, cash and non-cash coupons, and retroactive price reductions (including to governmental entities or agencies, purchasers, reimbursers, customers, distributors, wholesalers, and group purchasing and managed care organizations
or entities (and other similar entities and institutions); 

  

	 	b)	 credits or allowances, if any, on account of price adjustments, recalls, claims, damaged goods, rejections or
returns of items previously sold (including Company Products returned in connection with recalls or withdrawals) and amounts written off by reason of Bad Debt; provided, that if the debt is thereafter paid, the corresponding amount will be added to
the Net Sales of the period during which it is paid; 

  

	 	c)	 rebates (or their equivalent), administrative fees, and any other similar allowances granted or paid by
Company, its Affiliates or Licensees (including to governmental authorities, purchasers, reimbursers, customers, distributors, wholesalers, and managed care organizations and entities (and other similar entities and institutions) that effectively
reduce the selling price or gross sales of the Company Product; 

  

	 	d)	 insurance, customs charges, freight, postage, shipping, handling, and other transportation costs incurred by
Company, its Affiliates or Licensees in shipping Company Products; 

  

	 	e)	 to the extent not already deducted or excluded from the gross amounts invoiced, import taxes, export taxes,
excise taxes, sales taxes, value-added taxes, consumption taxes, duties or other taxes levied on, absorbed, determined, and/or imposed with respect to such sales, including pharmaceutical excise taxes (such as those imposed by the United States
Patient Protection and Affordable Care Act of 2010 (Pub. L. No. 111-48) and other comparable laws), but excluding income or net profit taxes or franchise taxes of any kind; and 

 

	 	f)	 other similar or customary deductions taken in the ordinary course of business in accordance with GAAP.

 Net Sales will be determined in accordance with GAAP except that GAAP compliance will not be required with
respect to the deduction of pharmaceutical excise taxes described in clause (e) above. Net Sales will not be imputed to transfers of Company Products for use in clinical trials, non-clinical development
activities, or other development activities that might be required by regulatory authorities with respect to Company Products, for bona fide charitable purposes, for compassionate use, for indigent patient programs, or as free samples. 

Notwithstanding the foregoing, in the event a Company Product contains another active ingredient that is not a Company Product itself, which Company Product
is sold as a unit at a single price either as a fixed dosage form or as separate dosage forms (such Company Product, a “Combination Product”), Net Sales of such Company Product for a particular country for the purpose of determining
royalties due hereunder shall be calculated by the Company using commercially reasonable accounting practices. 

“Post-IPO IP” shall mean Company IP that (a) was discovered or developed or (b) has a
priority date (in the case of a patent or patent application) after the effective date of the registration statement with respect to an initial public offering of the Company’s common stock pursuant to an effective registration statement under
the Securities Act of 1933. 
 “Pre-Acquisition IP” shall mean Company IP that (a) was
discovered or developed or (b) has a priority date (in the case of a patent or patent application) prior to the closing of an Acquisition of the Company. 

Section 2: Payments/Termination 

2.1 Payments to MPM Charitable Foundation. Within 120 days of the End of the Year, the Company agrees to pay to the MPM Charitable Foundation 0.5% of all global Net Sales of any Company Products received by the Company, its Licensees or its Affiliates during the prior calendar year. The
Company’s payment obligations to the MPM Charitable Foundation under this Section 2.1 shall terminate immediately upon the authorization by the board of directors (or similar governing body) of the MPM Charitable Foundation or the winding
up or dissolution of the MPM Charitable Foundation, or earlier as provided in Section 2.3. 
 2.2 Payments to Optimus. Within 120
days of the End of the Year, the Company agrees to pay to Optimus 0.5% of all global Net Sales of any Company Products received by the Company, its Licensees or its Affiliates during the prior
calendar year. The Company’s payment obligations to Optimus under this Section 2.2 shall terminate immediately upon the expiration or termination of the Contribution Agreement relating to the Quality and Access Initiative for Health in
Resource Poor Settings between Optimus and Oncology Impact Fund (Cayman) Management L.P. (“OIF Management”), or earlier as provided in Section 2.3. 

2.3 Termination/Step-Down. Notwithstanding the foregoing, Company’s obligation to pay royalties under Sections 2.1 and 2.2 for a
Company Product shall terminate on a country-by-country basis upon the later of (i) the date that is the twelfth
(12th) anniversary of the first commercial sale of that Company Product in such country, and (ii) the expiration of the last to 

 
expire issued patent claim of any Pre-Acquisition IP (other than Post-IPO IP) covering the composition or use of
such Company Product in such country (the “Royalty Term”). If the Royalty Term pursuant to clause (i) of this Section 2.3 exceeds the Royalty Term pursuant to clause (ii), the royalty rates under Sections 2.1 and 2.2 shall each
be reduced by fifty percent (50%) for the remainder of the Royalty Term, such that the new royalty rates under Section 2.1 and 2.2 shall be 0.25% each for the remainder of the Royalty Term. If MPM Oncology Impact Management GP, LP ceases for
any reason to serve as the general partner for OIF Management, then this Agreement shall terminate immediately. 
 2.4 Currency of
Payments. All payments under this Agreement shall be paid in U.S. dollars by wire transfer to an account designated by the receiving party (which account the receiving party may update from time to time in writing). 

2.5 Currency; Withholding Tax Matters. In the event that any of the payments made by the Company under this Agreement become subject to
withholding taxes under the laws of any jurisdiction, the Company shall deduct and withhold the amount of such taxes for the account of the applicable Charitable Foundation to the extent required by law, such payment to the applicable Charitable
Foundation shall be reduced by the amount of taxes deducted and withheld, and the Company shall pay the amount of such taxes to the proper governmental authority in a timely manner. Any such withholding taxes required under applicable law to be paid
or withheld shall be an expense of, and borne solely by, the applicable Charitable Foundation. 
 2.6 Confidentiality. All information
regarding Net Sales and other information disclosed by or on behalf of the Company under this Agreement shall be deemed to be the confidential information of the Company, and each Charitable Foundation shall not use such information for any purpose
or disclose such information to any third party, in each case during or after the term of this Agreement. 
 Section 3: Miscellaneous

 3.1 Binding Agreement and Assignment. This Agreement shall be binding upon and inure to the benefit of the Company and
its successors and assigns. The Company may not transfer, assign or sell any rights to commercialize any Company Products (other than to trade customers) without securing from the transferee,
assignee or acquirer, as the case may be, an acknowledgement of its continuing obligations under this Agreement. The Charitable Foundations may not assign any of their rights or obligations under this Agreement to any individual or entity without
the express written prior consent of the Company.
 3.2 Entire Agreement, Headings, and Modification. This Agreement contains the
entire understandings of the parties with respect to the subject matter herein, and supersedes all previous agreements (whether oral or written), negotiations, and discussions among the parties with respect to such subject matter. The
descriptive headings of the sections of this Agreement are inserted for convenience only and shall not control or affect the meaning or construction of any provision hereof. Any modifications or amendments to this Agreement must be made in
writing and signed by all parties. 

 3.3 Choice of Law. This Agreement shall be construed, governed, interpreted, and
applied in accordance with the laws of the Commonwealth of Massachusetts, exclusive of its conflicts of law provisions. Any unresolved controversy or claim arising out of or relating to this Agreement shall be submitted to arbitration by one
arbitrator mutually agreed upon by the parties, and if no agreement can be reached within 30 days after names of potential arbitrators have been proposed by the American Arbitration Association (the “AAA”), then by one arbitrator having
reasonable experience in licensing and royalty transactions who is chosen by the AAA. The arbitration shall take place in Boston, Massachusetts, in accordance with the AAA rules then in effect, and judgment upon any award rendered in such
arbitration will be binding and may be entered in any court having jurisdiction thereof. 
 3.4 Waiver. The waiver by any party
of the breach of any covenant or provision in this Agreement shall not operate or be construed as a waiver of any subsequent breach by such party. 

3.5 Severability. In the event a court of competent jurisdiction declares any term or provision of this Agreement to be invalid or
unenforceable for any reason, this Agreement will remain in full force and effect, and either: (a) the invalid or unenforceable provision(s) will be modified to the minimum extent necessary to make such provision(s) valid and enforceable; or
(b) if such a modification is not possible, this Agreement will be interpreted as if such invalid or unenforceable provision(s) were not a part of this Agreement. 

3.6 Counterparts. This Agreement may be executed in any number of counterparts, all of which will constitute one and the same
instrument, and will be an original of this Agreement. 
 (The remainder of this page is intentionally left blank. The signature pages
follow.) 

 IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto through their duly authorized
officers as of the Effective Date. 
  

			
	[Cullinan Asset Subsidiary]

 
			
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 [Royalty Transfer
Agreement] 

			
	MPM ONCOLOGY CHARITABLE FOUNDATION, INC.

			
		
	By:	 	  

	Name:	 	
	Title:	 	

			
	
	UBS OPTIMUS FOUNDATION

			
		
	By:	 	  

	Name:	 	
	Title:	 	
		
	And	 	
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 [Royalty Transfer
Agreement]EX-10.1

 Exhibit 10.1 
  

 
 December 15, 2020 

Mr. Michael Dorah 
 101 Curry Ave #502 

Royal Oak, MI 48067 
 Dear Michael, 

I am pleased to extend the following offer of employment to you as Senior Vice President and North America President for Superior Industries International,
Inc (the “Company” or “Superior”). In this position, you will be based out of our corporate headquarters in Southfield, Michigan, and will report directly to me. 

Compensation and Benefits 
 You will be paid, effective
from your date of hire, a base salary in the amount of $400,000 per annum (less the required withholding taxes and other statutory deductions) on a semi-monthly basis. This salary will be the basis for all benefit purposes. 

You will receive a car allowance of $9,600 per annum (less the required withholding taxes and other statutory deductions) on a monthly basis. The car
allowance is payable on the first pay period of each month. The car allowance will be treated as taxable income. 
 In addition, you will be eligible to
participate in the following Superior Industries Incentive Compensation Programs: 
  

	 	-	 Under our Annual Incentive Performance Program (AIPP), you will be eligible for a discretionary performance
bonus with an annual on-target bonus opportunity of 55% of your base salary. For 2021, the annual on-target value will be based on 12 months of eligibility and subject
to Board discretion. All earned bonuses are typically paid before March 15th of the following year and are based on the company’s performance as well as your individual performance. 

 

	 	-	 Subject to final approval by the Compensation Committee, as Senior Vice President and President North America,
you are eligible to participate in the Company’s Long-Term Incentive program as administered by Superior’s Compensation and Benefits Committee of the Board of Directors (“Committee”) with a target opportunity of 110% of your base
salary, beginning with the 2021-2023 Long-Term Incentive grant. 

 You will be eligible to participate in the Company’s benefit
program, such as medical, dental, vision, life and long-term disability insurance plans, with eligibility beginning on the first day of the calendar month following your date of hire. A 401(K) plan with a company match is also offered to assist you
in your long-term financial planning on the first day of the calendar month following 60 days of employment. The benefit programs are reviewed annually and subject to change at the discretion of the Company. 

As a Named Executive Officer of the Company, and subject to final approval by the Compensation Committee, you will participate in the Executive Change in
Control Severance Plan (the “Plan”). 

 Vacation 

You will accrue four weeks of paid vacation per year. For 2021, you will be eligible for 4.0 weeks of paid vacation. 

Start date 
 Your start date of employment will be no
later than January 11, 2021. 
 Policies 
 You will
be provided with the Company’s Code of Conduct and policies (collectively, the “Policies”) relating to your employment, and you agree to abide by all Policies in place throughout your employment and to execute any and all documents
related to the Company’s Policies as may be presented to you from time to time throughout your employment. The Company may, in its sole discretion, choose to add new Policies and change the terms of any of its existing Policies. 

Contingencies 
 This offer is contingent upon the
successful completion of the pre-employment drug screen; satisfactory results being obtained from the verifications of work history, and criminal background and credit checks; and the final approval of the
Superior Board of Directors. 
 The Immigration Reform and Control Act of 1986 requires Superior to verify the identity of every new employee and their
legal right to work in the United States. Your continued employment is conditional upon your ability to provide the necessary proof as indicated on the backside of the Employment Eligibility Verification Form
(I-9). 
 This offer will be withdrawn if any of the above conditions are not satisfied. 

Your employment will be conditional upon your signing the Company’s standard onboarding documents, including a
Non-Disclosure Agreement and acknowledgements of the Employee Handbook and Code of Conduct. 
 Employment

 Employment with the Company is at-will and is not for any fixed period of time. Employees may terminate their
employment at any time for any reason. Similarly, the Company may terminate any individual’s employment at any time for any reason. Your employment will be conditional upon your signing an agreement to your
at-will employment status. 
 If you find the terms of our offer acceptable, please acknowledge by signing and
returning one copy of this letter to me. This letter represents all terms associated with this offer of employment. 
 Michael, I want you to know that the
directors and employees that met with you at Superior are very excited about you joining the company. 
  

	
	Sincerely,
	
	/s/Majdi Abulaban
	
	Majdi Abulaban
	President and Chief Executive Officer

  

					
	I hereby accept this offer of employment:	 		 	
			
	/s/ Michael Dorah	 		 	 December 15, 2020

	Michael Dorah	 		 	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]